Route of Administration Segment Analysis: Topical (Largest Segment) vs Local Ocular (intravitreal) (Fastest-Growing Segment)

The topical segment dominated the ophthalmology drugs market, accounting for 61.16% in 2026. Its leading position is supported by the widespread use of eye drops and ophthalmic ointments as first-line treatments for a broad range of ocular disorders, including infections, allergies, glaucoma, and dry eye disease. Topical formulations offer convenient administration, improved patient adherence, and targeted drug delivery with limited systemic exposure, making them the preferred option for both physicians and patients. Continuous advancements in formulation technologies that improve drug retention and therapeutic effectiveness further reinforce the segment’s dominant position.

The local ocular (intravitreal) segment is expected to register the fastest growth during the forecast period. Increasing adoption of intravitreal therapies for retinal disorders requiring precise drug delivery has significantly expanded the use of this administration route. The growing prevalence of vision-threatening diseases, coupled with rising demand for targeted treatments capable of delivering sustained therapeutic effects directly to the eye, continues to drive the rapid expansion of this segment.

Distribution Channel Segment Analysis: Hospital Pharmacies (Largest Segment) vs Online Pharmacies (Fastest-Growing Segment)

Holding the largest share of the ophthalmology drugs market, hospital pharmacies accounted for 61.59% in 2026. Their leadership is driven by the high volume of prescription ophthalmic medications dispensed through hospitals, particularly for patients receiving specialized eye care, surgical procedures, and advanced retinal treatments. Hospital pharmacies also provide direct access to prescription therapies requiring clinical supervision while ensuring appropriate storage, handling, and patient counseling. Their close integration with ophthalmology departments further strengthens their role as the primary distribution channel.

Online pharmacies are anticipated to experience the fastest growth over the forecast period. The increasing adoption of digital healthcare platforms and growing consumer preference for convenient medicine purchasing have accelerated demand through online channels. Expanded home delivery services, improved accessibility to prescription refills, and the availability of digital consultation services are encouraging more patients to obtain ophthalmic medications through e-commerce platforms.

Therapeutic Class Segment Analysis: Anti-VEGF Agents (Largest & Fastest-Growing Segment)

The ophthalmology drugs market was led by the anti-VEGF agents segment, which captured 41.15% in 2026, while also emerging as the fastest-growing therapeutic class. The segment's strong performance is driven by the increasing burden of retinal diseases that require therapies capable of slowing disease progression and preserving vision. Growing awareness regarding early diagnosis, wider access to specialized ophthalmic care, and continuous innovation in biologic treatments have further strengthened demand. As healthcare providers increasingly prioritize targeted therapies that deliver effective long-term disease management, anti-VEGF agents continue to reinforce both their dominant market position and sustained growth trajectory.